Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Doctors looking at MRI scans to evaluate a glioblastoma.

Optimizing Glioblastoma Imaging: Enhancing MRI Efficiency and Quality with Deep Learning

This study investigates the use of deep learning (DL) to optimize MRI protocols for glioblastoma patients, aiming to reduce scan time and improve image quality.

Glioblastomas are aggressive brain tumors requiring frequent MRI monitoring, which can be challenging due to lengthy scan times and motion artifacts. Traditional methods to shorten scan times, like parallel acquisition techniques (PAT) and compressed sensing (CS), have limitations such as reduced signal-to-noise ratio and overly smooth images.

The study, involving 33 patients, found that DL-optimized MRI sequences reduced scan time by 30% while enhancing image quality and maintaining diagnostic accuracy. These improvements are particularly beneficial for patients who struggle with lengthy MRI procedures, offering a promising advancement in glioblastoma care.

Read more about the study here.

Related Resources

Related Resources

WUSTL: Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations

In this retrospective study utilizing the mint Lesion™ software[1], researchers found that routine clinical interpretations frequently resulted in the…

A doctor pushes a lying patient into the LDCT device

Early lung cancer detection through LDCT screening as a potential way to improve patient outcomes in Germany

The establishment of a nation-wide lung cancer screening program in Germany has been a subject of considerable interest and debate among healthcare…

A screenshot of a structured report from mint Lesion™

Tumor Growth Rate Modeling: A Novel Approach to Evaluating the Efficacy of Cancer Therapies

The 2020 review of Clinical Trial Evidence Supporting US Food and Drug Administrative Approval of Novel Cancer Therapies Between 2000 and 2016…